Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine 2009 - 2012
  • M.D., Harvard Medical School 2009
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Medical Oncology, Medicine 2015 - 2017
• Research
• 

  Selected Grants

  • A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564) awarded by Merck 2018 - 2023
  • A Salvage Trial of AR Inhibition with ADT and Apalutamide with Docetaxel followed by Radiation Therapy in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (¿STARTAR¿) awarded by Janssen Pharmaceutica, Inc. 2018 - 2023
  • Merrimack MM-310-01-01-01 awarded by Merrimack Pharmaceuticals 2017 - 2022
  • An Open-Label Study of Rovalpituzumab awarded by AbbVie Inc. 2017 - 2022
  • A first in human study of repeat dosing with REGN2810 a fully human antibody to programmed death - 1 (PD-1) as single therapy and in combination with selected awarded by Regeneron Pharmaceuticals, Inc. 2016 - 2021
  • Phase II study of AGS-16C3F vs Axitinib in Metastatic Renal Cell Carcinoma awarded by Astellas Pharma Global Development, Inc 2016 - 2021
  • Conditional lethality of copper and disulfiram as a therapeutic modality for prostate cancer awarded by V Foundation for Cancer Research 2016 - 2020
  • Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer awarded by National Institutes of Health 2014 - 2020
  • CTC-Immune Checkpoints awarded by Janssen Research & Development, LLC 2016 - 2020
  • A Phase I/II open label multicenter study of the safety and efficacy of LAG525 single agent in combination with PDR001 adminitered to patients awarded by Novartis Pharmaceuticals Corporation 2015 - 2020
  • A Retrospective Study to Evaluate the Clinical Effectiveness of the OmniSeq Immune Advance Test to Predict Response to Checkpoint Inhibitors awarded by OmniSeq, Inc 2017 - 2019
  • A study is to develop a retrospective database to study the PGDx TMB +MSI assay associated with clinical responses to immune checkpoint inhibitors (CPIs) awarded by Personal Genome Diagnostics, Inc. 2017 - 2019
  • A Phase 1b, open label, prospective, non-randomized,single center study of conditional lethalithy to copper as a therapeutic modality in prostate cancer awarded by Cantex Pharmaceuticals, Inc. 2017 - 2019
  • Retrospective analysis of docetaxel in castration sensitive setting awarded by H. Lee Moffitt Cancer Center & Research Institute 2017 - 2019
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Labriola, Matthew K., Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma..” Clinical Genitourinary Cancer, February 5, 2019. https://doi.org/10.1016/j.clgc.2019.01.017.
       Full Text
    • Zhang, Tian, Daniel J. George, and Andrew J. Armstrong. “Precision Medicine Approaches When Prostate Cancer Akts Up..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 25, no. 3 (February 2019): 901–3. https://doi.org/10.1158/1078-0432.ccr-18-2491.
       Full Text
    • Conroy, Jeffrey M., Sarabjot Pabla, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, et al. “Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors..” Journal for Immunotherapy of Cancer 7, no. 1 (January 24, 2019). https://doi.org/10.1186/s40425-018-0489-5.
       Full Text
    • Zhang, Tian, Andrew J. Armstrong, Daniel J. George, and Jiaoti Huang. “The promise of immunotherapy in genitourinary malignancies..” Precision Clinical Medicine 1, no. 3 (December 19, 2018): 97–101. https://doi.org/10.1093/pcmedi/pby018.
       Full Text
    • Bakthavatsalam, Subha, Mark L. Sleeper, Azim Dharani, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Leveraging γ-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells..” Angewandte Chemie (International Ed. in English) 57, no. 39 (September 2018): 12780–84. https://doi.org/10.1002/anie.201807582.
       Full Text
    • Labriola, Matthew, Wen-Chi Foo, Daniel J. George, and Tian Zhang. “Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report..” Clinical Genitourinary Cancer 16, no. 3 (June 2018): e509–12. https://doi.org/10.1016/j.clgc.2018.02.017.
       Full Text
    • Myung, Ja Hye, Michael J. Eblan, Joseph M. Caster, Sin-Jung Park, Michael J. Poellmann, Kyle Wang, Kevin A. Tam, et al. “Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 24, no. 11 (June 2018): 2539–47. https://doi.org/10.1158/1078-0432.ccr-17-3078.
       Full Text
    • Humeniuk, Michael S., Rajan T. Gupta, Patrick Healy, Megan McNamara, Sundhar Ramalingam, Michael Harrison, Daniel George, Tian Zhang, Yuan Wu, and Andrew J. Armstrong. “Platinum sensitivity in metastatic prostate cancer: does histology matter?.” Prostate Cancer and Prostatic Diseases 21, no. 1 (April 2018): 92–99. https://doi.org/10.1038/s41391-017-0017-6.
       Full Text
    • Austin, R Garland, Tony Jun Huang, Mengxi Wu, Andrew J. Armstrong, and Tian Zhang. “Clinical utility of non-EpCAM based circulating tumor cell assays..” Advanced Drug Delivery Reviews 125 (February 2018): 132–42. https://doi.org/10.1016/j.addr.2018.01.013.
       Full Text
    • Koshkin, Vadim S., Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, et al. “Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma..” Journal for Immunotherapy of Cancer 6, no. 1 (January 29, 2018). https://doi.org/10.1186/s40425-018-0319-9.
       Full Text  Open Access Copy
    • Zhu, Jason, Andrew J. Armstrong, Terence W. Friedlander, Won Kim, Sumanta K. Pal, Daniel J. George, and Tian Zhang. “Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond..” Journal for Immunotherapy of Cancer 6, no. 1 (January 25, 2018). https://doi.org/10.1186/s40425-018-0314-1.
       Full Text  Open Access Copy
    • Tian, Xi, Michael E. Werner, Kyle C. Roche, Ariel D. Hanson, Henry P. Foote, Stephanie K. Yu, Samuel B. Warner, et al. “Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds..” Nat Biomed Eng 2 (2018): 443–52.
       Link to Item
    • Zhu, Jason, Matthew Tucker, Endi Wang, Joel S. Grossman, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer..” Clinical Genitourinary Cancer 15, no. 6 (December 2017): e1137–41. https://doi.org/10.1016/j.clgc.2017.07.005.
       Full Text  Open Access Copy
    • Zhang, T., and A. J. Armstrong. “The who, what, and how of cabazitaxel treatment in metastatic castration-resistant prostate cancer.” Journal of Clinical Oncology 35, no. 28 (October 1, 2017): 3175–77. https://doi.org/10.1200/JCO.2017.74.7931.
       Full Text
    • Zhang, Tian, and Andrew J. Armstrong. “The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 35, no. 28 (October 2017): 3175–77. https://doi.org/10.1200/jco.2017.74.7931.
       Full Text
    • Humeniuk, Michael S., Tian Zhang, and Andrew J. Armstrong. “Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers..” Cancer 123, no. 18 (September 15, 2017): 3441–44. https://doi.org/10.1002/cncr.30806.
       Full Text  Link to Item
    • Min, Yuanzeng, Kyle C. Roche, Shaomin Tian, Michael J. Eblan, Karen P. McKinnon, Joseph M. Caster, Shengjie Chai, et al. “Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy..” Nature Nanotechnology 12, no. 9 (September 2017): 877–82. https://doi.org/10.1038/nnano.2017.113.
       Full Text
    • Ramalingam, Sundhar, Michael S. Humeniuk, Rachel Hu, Julia Rasmussen, Patrick Healy, Yuan Wu, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer..” Urol Oncol 35, no. 6 (June 2017): 418–24. https://doi.org/10.1016/j.urolonc.2016.12.016.
       Full Text  Link to Item
    • Tian, Jing, Yuangzeng Min, Zachary Rodgers, Xiaomeng Wan, Hui Qiu, Yu Mi, Xi Tian, et al. “Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer..” Nanomedicine : Nanotechnology, Biology, and Medicine 13, no. 3 (April 2017): 1301–7. https://doi.org/10.1016/j.nano.2016.11.007.
       Full Text
    • Zhang, Tian, Se Eun Park, Cierra Hong, and Daniel J. George. “Cabozantinib in genitourinary malignancies..” Future Oncology (London, England) 13, no. 8 (April 2017): 755–65. https://doi.org/10.2217/fon-2016-0358.
       Full Text
    • Caster, Joseph M., Artish N. Patel, Tian Zhang, and Andrew Wang. “Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials..” Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology 9, no. 1 (January 2017). https://doi.org/10.1002/wnan.1416.
       Full Text
    • Zhang, Tian, Jun Gong, Manuel Caitano Maia, and Sumanta K. Pal. “Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma..” American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting 37 (January 2017): 337–42. https://doi.org/10.14694/edbk_175572.
       Full Text
    • Tian, Xi, Samuel B. Warner, Kyle T. Wagner, Joseph M. Caster, Tian Zhang, Patricia Ohana, Alberto A. Gabizon, and Andrew Z. Wang. “Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy..” International Journal of Radiation Oncology, Biology, Physics 96, no. 3 (November 2016): 547–55. https://doi.org/10.1016/j.ijrobp.2016.06.2457.
       Full Text
    • Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew B. Nixon. “Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies..” Urologic Oncology 34, no. 11 (November 2016): 510–18. https://doi.org/10.1016/j.urolonc.2016.06.020.
       Full Text
    • Shao, Zhiying, Andrew Z. Wang, Daniel J. George, and Tian Zhang. “Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma..” Asian Journal of Urology 3, no. 4 (October 2016): 268–77. https://doi.org/10.1016/j.ajur.2016.08.013.
       Full Text
    • Hu, Rachel, Daniel J. George, and Tian Zhang. “What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence..” Therapeutic Advances in Urology 8, no. 4 (August 2016): 272–78. https://doi.org/10.1177/1756287216645314.
       Full Text
    • Kamal, A., T. Zhang, S. Power, and P. K. Marcom. “Is advanced imaging in early-stage breast cancer ever warranted? Reconciling clinical judgment with common quality measures.” Jnccn Journal of the National Comprehensive Cancer Network 14, no. 8 (August 1, 2016): 993–98. https://doi.org/10.6004/jnccn.2016.0106.
       Full Text
    • Kamal, Arif, Tian Zhang, Steve Power, and P Kelly Marcom. “Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures..” Journal of the National Comprehensive Cancer Network : Jnccn 14, no. 8 (August 2016): 993–98. https://doi.org/10.6004/jnccn.2016.0106.
       Full Text
    • Ware, Kathryn E., Jason A. Somarelli, Daneen Schaeffer, Jing Li, Tian Zhang, Sally Park, Steven R. Patierno, et al. “Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer..” Oncotarget 7, no. 31 (August 2016): 50507–21. https://doi.org/10.18632/oncotarget.10476.
       Full Text  Open Access Copy
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Chandra Rao, Gabor Kemeny, John H. Strickler, James L. Abbruzzese, et al. “Development of a Novel c-MET-Based CTC Detection Platform..” Mol Cancer Res 14, no. 6 (June 2016): 539–47. https://doi.org/10.1158/1541-7786.MCR-16-0011.
       Full Text  Open Access Copy  Link to Item
    • Au, Kin Man, Andrew Satterlee, Yuanzeng Min, Xi Tian, Young Seok Kim, Joseph M. Caster, Longzhen Zhang, Tian Zhang, Leaf Huang, and Andrew Z. Wang. “Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic..” Biomaterials 82 (March 2016): 178–93. https://doi.org/10.1016/j.biomaterials.2015.12.018.
       Full Text  Link to Item
    • Zhu, Jason, Carter T. Davis, Sandra Silberman, Neil Spector, and Tian Zhang. “A role for the androgen receptor in the treatment of male breast cancer..” Critical Reviews in Oncology/Hematology 98 (February 2016): 358–63. https://doi.org/10.1016/j.critrevonc.2015.11.013.
       Full Text
    • Zhang, Tian, and Andrew J. Armstrong. “Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer..” Curr Oncol Rep 18, no. 1 (January 2016). https://doi.org/10.1007/s11912-015-0490-9.
       Full Text  Link to Item
    • Zhu, Jason, Tian Zhang, Radhika Shah, Arif H. Kamal, and Michael J. Kelley. “Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians..” Journal of Cancer Education : The Official Journal of the American Association for Cancer Education 30, no. 4 (December 2015): 774–78. https://doi.org/10.1007/s13187-015-0798-z.
       Full Text
    • Zhang, Tian, and Andrew J. Armstrong. “Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 21, no. 20 (October 2015): 4505–7. https://doi.org/10.1158/1078-0432.ccr-15-1613.
       Full Text  Open Access Copy
    • Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Michael R. Harrison, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer..” Clin Genitourin Cancer 13, no. 4 (August 2015): 392–99. https://doi.org/10.1016/j.clgc.2015.01.004.
       Full Text  Link to Item
    • Zhang, Tian, Elizabeth L. Boswell, Shannon J. McCall, and David S. Hsu. “Mismatch repair gone awry: Management of Lynch syndrome..” Critical Reviews in Oncology/Hematology 93, no. 3 (March 2015): 170–79. https://doi.org/10.1016/j.critrevonc.2014.10.005.
       Full Text
    • Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew J. Armstrong. “Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer..” Expert Opin Pharmacother 16, no. 4 (March 2015): 473–85. https://doi.org/10.1517/14656566.2015.995090.
       Full Text  Link to Item
    • Zhu, J., T. Zhang, R. Shah, A. H. Kamal, and M. J. Kelley. “Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians.” Journal of Cancer Education 30, no. 4 (2015): 774–78. https://doi.org/10.1007/s13187-015-0798-z.
       Full Text
    • Aggarwal, Rahul, Tian Zhang, Eric J. Small, and Andrew J. Armstrong. “Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes..” Journal of the National Comprehensive Cancer Network : Jnccn 12, no. 5 (May 2014): 719–26. https://doi.org/10.6004/jnccn.2014.0073.
       Full Text
    • Boggan, Joel C., Tian Zhang, Chris Derienzo, Karen Frush, and Kathryn Andolsek. “Standardizing and Evaluating Transitions of Care in the Era of Duty Hour Reform: One Institution's Resident-Led Effort..” Journal of Graduate Medical Education 5, no. 4 (December 2013): 652–57. https://doi.org/10.4300/JGME-D-12-00287.
       Full Text
    • Zhang, Tian, Shiva K. Das, Diane R. Fels, Katherine S. Hansen, Terence Z. Wong, Mark W. Dewhirst, and Gordana Vlahovic. “PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions..” Ajr Am J Roentgenol 201, no. 5 (November 2013): W698–706. https://doi.org/10.2214/AJR.12.9698.
       Full Text  Link to Item
    • Zhang, Tian, and Andrew J. Armstrong. “Clinical phenotypes of castration-resistant prostate cancer..” Clinical Advances in Hematology & Oncology : H&O 11, no. 11 (November 2013): 707–18.
    • Zhang, Tian, Andrew Schneider, Erika P. Hamilton, Krish Patel, Arif H. Kamal, Gary H. Lyman, and Jeffrey M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials..” Breast Cancer Research and Treatment 139, no. 3 (June 15, 2013): 845–50. https://doi.org/10.1007/s10549-013-2590-2.
       Full Text
    • Zhang, T., A. Schneider, E. P. Hamilton, K. Patel, A. H. Kamal, G. H. Lyman, and J. M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials.” Breast Cancer Research and Treatment 139, no. 3 (2013): 845–50. https://doi.org/10.1007/s10549-013-2590-2.
       Full Text
    • DeRienzo, Christopher M., Karen Frush, Michael E. Barfield, Priya R. Gopwani, Brian C. Griffith, Xiaoyin Jiang, Ankit I. Mehta, et al. “Handoffs in the era of duty hours reform: a focused review and strategy to address changes in the Accreditation Council for Graduate Medical Education Common Program Requirements..” Academic Medicine 87, no. 4 (April 2012): 403–10. https://doi.org/10.1097/acm.0b013e318248e5c2.
       Full Text
    • Werner, Michael E., Shrirang Karve, Rohit Sukumar, Natalie D. Cummings, Jonathan A. Copp, Ronald C. Chen, Tian Zhang, and Andrew Z. Wang. “Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis..” Biomaterials 32, no. 33 (November 2011): 8548–54. https://doi.org/10.1016/j.biomaterials.2011.07.067.
       Full Text  Link to Item
    • Zhang, Tian, Diane R. Fels, Katherine S. Hansen, Shiva K. Das, Terence Z. Wong, Mark W. Dewhirst, and Gordana Vlahovic. “62CUATSM AND 62CUPTSM PET IS A USEFUL IMAGING TOOL FOR HYPOXIA AND PERFUSION IN LUNG CANCER.” Journal of Thoracic Oncology 6, no. 6 (June 1, 2011): S919–20.
       Link to Item
    • Kamal, A., T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, and J. M. Peppercorn. “Outcomes in phase II trials of metastatic breast cancer: Where is the bar?.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).
    • Patel, K., A. Kamal, T. Zhang, A. Schneider, E. P. Hamilton, and J. M. Peppercorn. “The role of biologic therapy in phase II breast cancer clinical trials..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).
    • Schneider, A., T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, and J. M. Peppercorn. “Pharmaceutical involvement in phase II breast cancer clinical trials..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).
    • Zhang, T., E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, and J. M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29, no. 15_suppl (May 2011).

  • Book Sections

    • Zhang, T., and A. Z. Wang. “Biochemical failure in prostate cancer.” In Prostate Cancer: A Comprehensive Perspective, 807–11, 2013. https://doi.org/10.1007/978-1-4471-2864-9_67.
       Full Text

  • Conference Papers

    • Koontz, B. F., K. E. Hoffman, P. Healy, D. J. George, M. R. Harrison, T. Zhang, W. R. Lee, et al. “Two Year Outcomes of Short-Term Potent Androgen Blockade and Definitive Radiation for Intermediate to High Risk Localized Prostate Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 102:S100–S100. Elsevier BV, 2018. https://doi.org/10.1016/j.ijrobp.2018.06.256.
       Full Text
    • Ware, Kathryn E., Santosh Gupta, Jared Eng, Wen-Chi Foo, Lorin Crawford, Garland Austin, Bhairavy Puviindran, et al. “Abstract B038: Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer.” In Poster Presentations  Proffered Abstracts. American Association for Cancer Research, 2018. https://doi.org/10.1158/1538-7445.prca2017-b038.
       Full Text
    • George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP)..” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.
       Link to Item
    • Koontz, Bridget F., Karen E. Hoffman, Patrick Healy, Daniel J. George, Michael Roger Harrison, Tian Zhang, W Robert Lee, et al. “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer..” In Journal of Clinical Oncology, 36:11–11. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.11.
       Full Text
    • Zhang, Tian, Rebecca Garland Austin, Sally E. Park, Daniella Runyambo, Rengasamy Boominathan, Chandra Rao, Elizabeth Bronson, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer (mPC)..” In Journal of Clinical Oncology, 36:191–191. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.191.
       Full Text
    • Choueiri, T. K., T. Powles, T. Zhang, D. I. Quinn, J. E. Gschwend, S. S. Wan, and C. Poehlein. “KEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC).” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
       Link to Item
    • Zhang, T., M. Harrison, P. O’Donnell, A. Alva, N. Hahn, L. J. Appleman, J. Cetnar, et al. “Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC).” In Annals of Oncology, Vol. 28. OXFORD UNIV PRESS, 2017.
       Link to Item
    • Bakthavatsalam, Subha, Tian Zhang, and Katherine Franz. “Targeted prodrugs to manipulate copper biology of prostate cancer.” In Abstracts of Papers of the American Chemical Society, Vol. 254. AMER CHEMICAL SOC, 2017.
       Link to Item
    • Dharani, Azim, Subha Bakthavatsalam, Tian Zhang, and Katherine Franz. “Prostate cancer targeted prodrug based on copper prochelator.” In Abstracts of Papers of the American Chemical Society, Vol. 254. AMER CHEMICAL SOC, 2017.
       Link to Item
    • Ware, Kathryn E., Daneen Schaeffer, Tian Zhang, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Abstract 1847: AR-V7 regulation during epithelial plasticity.” In Cancer Research, 75:1847–1847. American Association for Cancer Research (AACR), 2015. https://doi.org/10.1158/1538-7445.am2015-1847.
       Full Text
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, John H. Strickler, et al. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal (GI) and genitourinary (GU) malignancies..” In Journal of Clinical Oncology, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
       Link to Item
    • Zhang, Tian, Rengasamy Boominathan, Brad Foulk, Mark Carle Connelly, Chandra Rao, Gabor Kemeny, Herbert Hurwitz, Mariano A. Garcia-Blanco, and Andrew J. Armstrong. “Evaluation of a novel c-MET based circulating tumor cell (CTC) biomarker in patients with gastrointestinal malignancies..” In Journal of Clinical Oncology, 33:84–84. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.3_suppl.84.
       Full Text
    • Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC)..” In Journal of Clinical Oncology, 32:e16031–e16031. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16031.
       Full Text
    • Zhang, Tian, Steve Power, Paul K. Marcom, and Arif Kamal. “Is advanced imaging in early-stage breast cancer ever warranted? Exploring benchmarks for an ASCO Choosing Wisely quality measure..” In Journal of Clinical Oncology, 32:6503–6503. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.6503.
       Full Text
    • Zhang, Tian, Arif Kamal, and Michael J. Kelley. “Comparison of QOPI measure conformance between oncology fellows and attending physicians.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013. https://doi.org/10.1200/jco.2013.31.31_suppl.162.
       Full Text  Link to Item
    • Zhang, Tian, Shiva K. Das, Jeffrey Crawford, Terence Wong, Mark W. Dewhirst, and Gordana Vlahovic. “(62)cuatsm and (62)cuptsm PET is a useful imaging tool for hypoxia and perfusion in lung cancer..” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
       Link to Item
    • Kamal, A., T. Zhang, A. Schneider, K. Patel, E. P. Hamilton, P. K. Marcom, and J. M. Peppercorn. “Outcomes in phase II trials of metastatic breast cancer: Where is the bar?.” In Journal of Clinical Oncology, 29:2590–2590. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.2590.
       Full Text
    • Patel, K., A. Kamal, T. Zhang, A. Schneider, E. P. Hamilton, and J. M. Peppercorn. “The role of biologic therapy in phase II breast cancer clinical trials..” In Journal of Clinical Oncology, 29:e13048–e13048. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.e13048.
       Full Text
    • Schneider, A., T. Zhang, A. Kamal, K. Patel, E. P. Hamilton, and J. M. Peppercorn. “Pharmaceutical involvement in phase II breast cancer clinical trials..” In Journal of Clinical Oncology, 29:6104–6104. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.6104.
       Full Text
    • Zhang, T., E. P. Hamilton, A. Schneider, K. Patel, A. Kamal, and J. M. Peppercorn. “Prevalence and impact of correlative science in breast cancer phase II trials..” In Journal of Clinical Oncology, 29:1046–1046. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.1046.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.